- The 8 States Most Likely to Legalize Marijuana Next
- Behind Russia's Current Crisis: It's Not the Ruble, It's Putin
- Would you invest in the U.S. Postal Service?
- Why Jim Cramer Says it Could be Too Late to Enter the Stock Market Rally Now
- Apple (AAPL) Stock Declining Today Amid Allegations of Poor Working Conditions in China
Medivation now has a formidable competitor for prostate cancer therapy.
Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged.
Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.